<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.nanovip.com" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>Nanotechnology : Switzerland nanotechnology stocks</title>
 <link>http://www.nanovip.com/taxonomy/term/111/alpha</link>
 <description>Nanovip.com list of database content.</description>
 <language>en</language>
<item>
 <title>Actelion Ltd &amp; Actelion Pharmaceuticals Ltd</title>
 <link>http://www.nanovip.com/node/540</link>
 <description>&lt;div class=&quot;field field-type-text field-field-ticker-id&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Ticker Id&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-web-url&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Web url&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;http://www.actelion.com/&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-contact-email&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Contact Email&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;info@actelion.com&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-short-description&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Short description&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-street-address&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Street address&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;Gewerbestrasse 16&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-zip-or-postal-code&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Zip or postal code&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;4123&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-telephone&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Telephone&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;+41 61 565 65 65&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-fax&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Fax&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;+41 61 565 65 00&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-foundation-date&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Foundation date&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-ceo-president&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Ceo, president&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-number-of-employees&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Number of employees&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-long-description&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Long description&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
          &lt;div class=&quot;field-item&quot;&gt;&lt;p&gt;Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources based on first-in-class small molecule compounds. In doing so, Actelion is focusing on innovative treatments for highunmet medical needs, where Actelions new drugs can bring therapeutic advantage to patients and economic benefit for the community at large. Actelion also aims to maximize the value of its products, for example, by seeking additional indications for existing drugs. &lt;/p&gt;
&lt;p&gt;Actelion has established an infrastructure to develop, register and market its products in key markets worldwide. By doing so, Actelion is generating sustained profitability and ensuring a growth above industry average. When a product&#039;s potential indications could serve a patient population so large that Actelion could not adequately serve it with its own marketing force, the company may seek strategic partnerships with other pharmaceutical or biopharmaceutical companies.&lt;/p&gt;
&lt;/div&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-additional-commentaries-a&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Additional Commentaries and remarks&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;

&lt;div class=&quot;field field-type-text field-field-patents&quot;&gt;
  &lt;h3 class=&quot;field-label&quot;&gt;Patents&lt;/h3&gt;
  &lt;div class=&quot;field-items&quot;&gt;
      &lt;/div&gt;
&lt;/div&gt;
</description>
 <comments>http://www.nanovip.com/node/540#comments</comments>
 <category domain="http://www.nanovip.com/taxonomy/term/1013">Companies and Institutions</category>
 <category domain="http://www.nanovip.com/taxonomy/term/20">Biotechnology</category>
 <category domain="http://www.nanovip.com/taxonomy/term/101">Switzerland</category>
 <category domain="http://www.nanovip.com/taxonomy/term/515">Allschwil</category>
 <category domain="http://www.nanovip.com/nanotechnology-stocks/switzerland">Switzerland nanotechnology stocks</category>
 <pubDate>Sun, 20 Aug 2006 16:15:26 +0000</pubDate>
 <dc:creator>Benj</dc:creator>
 <guid isPermaLink="false">540 at http://www.nanovip.com</guid>
</item>
</channel>
</rss>
